Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15759764 | 0.88 | LMNA (0.30) | LMNACYP2D6 | |
| SCHEMBL12063910 | 0.85 | LMNA (0.38) | LMNACYP2D6 | |
| SCHEMBL13117304 | 0.84 | LMNA (0.31) | LMNACYP2D6 | |
| SCHEMBL24766845 | 0.78 | — | — | |
| SCHEMBL25920321 | 0.76 | LMNA (0.33) | LMNACYP2D6 | |
| SCHEMBL10296019 | 0.76 | LMNA (0.33) | LMNACYP2D6 | |
| SCHEMBL14943806 | 0.76 | LMNA (0.33) | LMNACYP2D6 | |
| SCHEMBL18737369 | 0.76 | LMNA (0.30) | LMNACYP2D6 | |
| SCHEMBL20172542 | 0.76 | LMNA (0.30) | LMNACYP2D6 | |
| SCHEMBL518099 | 0.74 | POLB (0.33) | POLBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102956-A1 | KETO-AMIDE-BASED FIBROBLAST ACTIVATION PROTEIN-TARGETED LIGAND LINKED TO AN IMAGING OR THERAPEUTIC AGENT, COMPOSITIONS AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| WO-2023157850-A1 | METHOD FOR PRODUCING OLEFIN SULFIDE | DIC株式会社 | 2023-08-24 | — | — | WO | disclosed |
| WO-2023109506-A1 | POLYMERIC STERICALLY HINDERED AMINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 天集化工助剂（沧州）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11552261-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022270549-A1 | NOVEL POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2022-12-29 | — | — | WO | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
| EP-1005463-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| US-6051571-A | NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6040444-A | Process for preparing furan nitrone compounds | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6015831-A | AUTOIMMUNE, NERVOUS SYSTEM, GASTROINTESTINAL, AND BRAIN DISORDERS; ANTIINFLAMMATORY AGENTS; ALZHEIMER*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5994396-A | Furansulfonic acid derivatives and pharmaceutical compositions containing the same | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| WO-1999059582-A1 | AMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5942507-A | REAGANTS FOR DETECTION FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1999036420-A1 | THIOPHENE NITRONE COMPOUNDS | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-07-22 | — | — | WO | disclosed |
| WO-1999009022-A1 | FURANSULFONIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5118736-A | Polymer stabilization against actinic radiation | CIBA-GEIGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | LMNA 215/4885CYP2D6 1941/4885POLB 2539/4885 |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | LMNA 3109/4885CYP2D6 4416/4885POLB 3508/4885 |
| US-11552261-B2 | Organic electroluminescent materials and devices | OCIAD1, OCIAD2, OSBP | LMNA 3112/4885CYP2D6 199/4885POLB 762/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | LMNA 2161/4885CYP2D6 426/4885POLB 498/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | LMNA 4394/4885CYP2D6 460/4885POLB 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.